Anticipated $-0.77 EPS for Madrigal Pharmaceuticals, Inc. (MDGL) as of May, 10

May 3, 2018 - By Carey Conley

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)’s earnings release is anticipated by WallStreet on May, 10, Zacks reports. The earnings per share diference is $0.27 or 54.00 % down from last years number. Previous year: $-0.5; Analysts forcast: $-0.77. 14.93 % negative EPS growth is what Wall Street’s forecasts after $-0.67 reported EPS last quarter. The stock decreased 0.19% or $0.22 during the last trading session, reaching $112.71.Currently Madrigal Pharmaceuticals, Inc. is uptrending after 574.52% change in last May 3, 2017. MDGL has also 9,247 shares volume. MDGL outperformed by 562.97% the S&P500.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases.The firm is valued at $1.60 billion. The company's lead candidate is MGL-3196, which is in Phase II clinical trials, a liver-directed thyroid hormone receptor-ß agonist used for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and familial hypercholesterolemia.Last it reported negative earnings. It is also developing MGL-3745, which is in pre-clinical stage, a THR-ß agonist that is in preclinical trials.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: